Labcorp will acquire the oncology diagnostics operations from BioReference Health as part of a push to expand in high-growth ...

Labcorp Holdings has signed a deal to buy certain assets of OPKO Health's BioReference Health unit for up to $225 million. Labcorp on Tuesday said it will pay $192.5 million at closing for ...

Labcorp Holdings Inc. LH, or Labcorp, is prioritizing key specialty testing areas, such as oncology, women’s health, autoimmune disease and neurology, aiming to tap into strong growth opportunities.

The liquid biopsy test enables oncologists to perform comprehensive genomic profiling to inform personalized treatment decisions – all from a simple blood draw. "Labcorp Plasma Complete delivers ...

Argus analyst David Toung raised the firm’s price target on Labcorp (LH) to $290 from $260 and keeps a Buy rating on the shares after its Q4 ...